A genetic polymorphism of the N-oxidation of trimethylamine in humans
- PMID: 3677545
- DOI: 10.1038/clpt.1987.201
A genetic polymorphism of the N-oxidation of trimethylamine in humans
Abstract
Trimethylamine (TMA) and its N-oxide (TMAO) are normal components of human urine. They are present in the diet and also derived from the enterobacterial metabolism of precursors such as choline. Dietary TMA is almost entirely metabolized to and excreted as TMAO. However, the extent to which TMA undergoes N-oxidation appears to be polymorphic in a British white population study (n = 169). Two propositi were identified with relative TMA N-oxidation deficiency that was further confirmed by oral challenge with TMA (600 mg). The study of the families of the two propositi, as well as those of two identified subjects with trimethylaminuria, under both normal dietary conditions and after oral TMA challenge strongly indicates that the conditions of impaired N-oxidation is inherited as a recessive trait. It is proposed that the N-oxidation of TMA in humans is polymorphic and under single gene diallelic control in which individuals who are homozygous for the variant allele exhibit marked N-oxidation deficiency and trimethylaminuria.
Similar articles
-
Trimethylaminuria: the detection of carriers using a trimethylamine load test.J Inherit Metab Dis. 1989;12(1):80-5. doi: 10.1007/BF01805534. J Inherit Metab Dis. 1989. PMID: 2501587
-
The N-oxidation of trimethylamine in a Jordanian population.Br J Clin Pharmacol. 1995 Feb;39(2):179-81. doi: 10.1111/j.1365-2125.1995.tb04427.x. Br J Clin Pharmacol. 1995. PMID: 7742158 Free PMC article.
-
Diagnosis of suspected trimethylaminuria by NMR spectroscopy.Clin Chim Acta. 2005 Jan;351(1-2):149-54. doi: 10.1016/j.cccn.2004.09.006. Clin Chim Acta. 2005. PMID: 15563884
-
Trimethylamine: metabolic, pharmacokinetic and safety aspects.Curr Drug Metab. 2005 Jun;6(3):227-40. doi: 10.2174/1389200054021807. Curr Drug Metab. 2005. PMID: 15975041 Review.
-
Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria.Curr Drug Metab. 2003 Apr;4(2):151-70. doi: 10.2174/1389200033489505. Curr Drug Metab. 2003. PMID: 12678693 Review.
Cited by
-
Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.Arch Toxicol. 2022 Aug;96(8):2145-2246. doi: 10.1007/s00204-022-03304-3. Epub 2022 Jun 1. Arch Toxicol. 2022. PMID: 35648190 Free PMC article. Review.
-
Drug Discovery and Development of Novel Therapeutics for Inhibiting TMAO in Models of Atherosclerosis and Diabetes.Front Physiol. 2020 Oct 29;11:567899. doi: 10.3389/fphys.2020.567899. eCollection 2020. Front Physiol. 2020. PMID: 33192565 Free PMC article. Review.
-
Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: 1H NMR spectroscopy and genetic testing.Orphanet J Rare Dis. 2019 Sep 18;14(1):222. doi: 10.1186/s13023-019-1174-6. Orphanet J Rare Dis. 2019. PMID: 31533761 Free PMC article.
-
Effect of Flavin-Containing Monooxygenase Genotype, Mouse Strain, and Gender on Trimethylamine N-oxide Production, Plasma Cholesterol Concentration, and an Index of Atherosclerosis.Drug Metab Dispos. 2018 Jan;46(1):20-25. doi: 10.1124/dmd.117.077636. Epub 2017 Oct 25. Drug Metab Dispos. 2018. PMID: 29070510 Free PMC article.
-
Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease.Drug Metab Dispos. 2016 Nov;44(11):1839-1850. doi: 10.1124/dmd.116.070615. Epub 2016 May 17. Drug Metab Dispos. 2016. PMID: 27190056 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
